Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation
Two-year follow-up results from an ongoing study on the safety and effectiveness of elexacaftor/tezacaftor/ivacaftor when used in real-world settings by people with cystic fibrosis
Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis (CF): a systematic review
Results from a clinical trial of the natural therapeutic alginate OligoG against Burkholderia lung infection in people with cystic fibrosis.
